Altimmune, Inc. Operating Income Loss

• Altimmune, Inc. showed an increase of +8.4% in Operating Income Loss from 2024 to 2025.
• This data is from Altimmune, Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2026.
• XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 16 years of available data (2010 to 2025), Altimmune, Inc.'s Operating Income Loss has declined by 301.2%.
• Historical annual values: Fiscal year 2025: -$94.49 million | Fiscal year 2024: -$103.17 million | Fiscal year 2023: -$95.93 million | Fiscal year 2022: -$87.74 million | Fiscal year 2021: -$96.91 million | Fiscal year 2020: -$54.80 million | Fiscal year 2019: -$21.46 million | Fiscal year 2018: -$42.83 million | Fiscal year 2017: -$52.05 million | Fiscal year 2016: -$11.09 million | Fiscal year 2015: -$3.40 million | Fiscal year 2014: -$10.19 million | Fiscal year 2013: -$10.84 million | Fiscal year 2012: -$6.27 million | Fiscal year 2011: -$11.73 million | Fiscal year 2010: -$23.55 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026